Related Experiment Video
Updated: Oct 28, 2025
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Quantum binding energies of checkpoint CTLA-4 in complex with the immuno-oncological drug ipilimumab
Ana Beatriz M L A Tavares1, E L Albuquerque2
1Departamento de Bioquímica, Universidade Federal do Rio Grande do Norte, 59072-970, Natal-RN, Brazil. anabmlat@gmail.com and Hospital das Clínicas, Universidade Federal de Pernambuco, 50.670-901, Recife-PE, Brazil.
Abstract:
Inhibition of the checkpoint protein CTLA-4 by the US-FDA's approved monoclonal antibody ipilimumab has delivered breakthrough therapies against a wide range of cancers, being an important issue for clinical research. To date, many structural properties of this drug have been unveiled. However, the binding energy features of the receptor CTLA-4 in complex with its drug inhibitor, based on crystallographic data, need a deeper understanding. Within this context, by employing quantum chemistry we investigate in silico the binding energy features of the checkpoint protein CTLA-4 in complex with its drug inhibitor, highlighting the most relevant residue-residue interactions, looking for new insights into the mechanisms of pathway blockade to further engineer its affinity and selectivity. Our computational results not only give a better understanding of the binding mechanisms, but also point to an efficient alternative towards the development of antibody-based drugs, leading to new treatments for cancer therapy based upon immunotherapy.
Insights
Computational quantum chemistry reveals key interactions between the CTLA-4 protein and ipilimumab. This deepens understanding of cancer immunotherapy mechanisms and aids in developing improved antibody-based cancer drugs.
Area of Science:
- Immunology
- Computational Chemistry
- Oncology
Background:
- Monoclonal antibody ipilimumab, an inhibitor of the CTLA-4 checkpoint protein, has revolutionized cancer therapy.
- While ipilimumab's structure is well-studied, a detailed understanding of CTLA-4's binding energy with its inhibitor is lacking.
- Crystallographic data provides a basis for further investigation into these interactions.
Purpose of the Study:
- To investigate the binding energy features of the CTLA-4 receptor in complex with ipilimumab using in silico quantum chemistry methods.
- To identify critical residue-residue interactions within the CTLA-4/ipilimumab complex.
- To gain new insights into the mechanisms of immune checkpoint blockade for potential drug engineering.
Main Methods:
- In silico quantum chemistry calculations were employed.
- Analysis focused on the binding energy of the CTLA-4/ipilimumab complex.
- Identification of key residue-residue interactions was performed.
Main Results:
- The study elucidated the binding energy features of the CTLA-4/ipilimumab complex.
- Significant residue-residue interactions contributing to the binding were highlighted.
- Computational results provided a deeper understanding of the binding mechanism.
Conclusions:
- The findings enhance comprehension of immune checkpoint inhibitor binding mechanisms.
- This research offers an efficient computational approach for developing novel antibody-based cancer therapeutics.
- The study paves the way for engineering improved affinity and selectivity in future immunotherapy drugs.
Related Concept Videos
01:27Tumor Immunotherapy
02:18The Equilibrium Binding Constant and Binding Strength